Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iCAR: HER2-CAR T Cells in HER2-Positive CNS Tumors
NCT02442297Phase 1Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2016
- Primary completion
- Apr 2022
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of HER2-specific CAR T cells in central nervous system tumor and brain tumor (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Dose Limiting Toxicity at 6 weeks. Started Apr 2016; status: active, not recruiting.
02
Drugs
HER2-specific CAR T cells
03
Conditions
central nervous system tumorbrain tumor
Beyond the preview
Go deeper on NCT02442297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442297.